Immunovant, Inc. (IMVT) stock
IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
$33.21−0.07 (-0.21%)
Close on Nov 17, 2026Market cap $6.86BP/E –Yield –
Immunovant r&d expenses
Research and development expenses are spending on new products and technology.
Immunovant's R&D Expenses for the twelve months ending Jun 30, 2026 was $498.09M, up 28.8% year over year. For fiscal 2026 it was $456.66M, up 26.5% from the year before. The highest annual figure on record is $456.66M in fiscal 2026.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $456.66M | +26.5% |
| FY2025 | Mar 31, 2025 | $360.92M | +69.5% |
| FY2024 | Mar 31, 2024 | $212.93M | +32.9% |
| FY2023 | Mar 31, 2023 | $160.26M | +57.4% |
| FY2022 | Mar 31, 2022 | $101.81M | +48.4% |
| FY2021 | Mar 31, 2021 | $68.60M | +43.1% |
| FY2020 | Mar 31, 2020 | $47.93M | +86.2% |
| FY2019 | Mar 31, 2019 | $25.73M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $142.63M | +40.9% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $142.29M | +51.9% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $98.92M | +4.7% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $114.25M | +17.5% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $101.20M | +34.1% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $93.65M | +41.8% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $94.52M | +95.5% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $97.27M | +102.8% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $75.47M | +49.2% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $66.06M | +27.4% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $48.34M | +14.4% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $47.96M | +27.1% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $50.58M | +77.9% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $51.84M | +62.1% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $42.25M | +42.0% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $37.74M | +76.7% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $28.43M | +52.0% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $31.99M | +71.8% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $29.76M | +41.1% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $21.36M | +78.4% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $18.71M | +10.5% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $18.62M | -2.6% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $21.09M | +14.2% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $11.98M | +50.3% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $16.92M | +120.3% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $19.12M | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $18.48M | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $7.97M | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $7.68M | – |
See a number that looks wrong?